PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.
Overview – Declines in AbbVie’s flagship product Humira due to biosimilar competition will be offset by the company’s robust portfolio of launch drugs.
Key themes –  Biosimilar launches in Europe and other international markets have negatively impacted Humira’s growth, but the brand could grow in 2020 and should have revenue stability until US biosimilar launches in 2023  AbbVie will see tremendous growth from Imbruvica, Skyrizi, Rinvoq, and Venclexta  Acquisition of Allergan, poised to close in 2020, will further diversify AbbVie’s revenues.
Model updates (3 August 2020)
Abicipar pegol forecast removed due to CRL in the US and the withdrawal of regulatory filings in Europe and Japan
Humira forecast adjusted higher in the US due to updated guidance from ABBV
Rinvoq forecast adjusted higher in the US due to strong launch trends
Botox forecast adjusted lower globally due to impact from COVID-19
Juvederm forecast adjusted lower globally due to impact from COVID-19
Veliparib forecast adjusted lower due to a pushout of estimated approval date.
Model updates (20 May 2020)
Humira forecast adjusted lower in the US due to changes in reimbursement mix and lower new patient starts
Mavyret forecast adjusted lower due to market dynamics in HCV
Added Allergan drugs to AbbVie forecast due to closing of merger, including:
– Lo Loestrin
Model updates (25 February 2020)
Humira forecast adjusted higher due to stronger US trends only partially offset by continued biosimilar impact internationally
Skyrizi forecast adjusted higher due to strong initial launch in moderate-to-severe plaque psoriasis
Rinvoq forecast adjusted lower in the near-term due to launch trend in moderate-to-severe rheumatoid arthritis
Imbruvica forecast adjusted higher due to continued share gains in all lines of therapy in chronic lymphocytic leukemia and all approved indications
Venclexta forecast adjusted lower due to improved forecast for Imbruvica and market trends in chronic lymphocytic leukemia
Mavyret forecast adjusted lower due to lower treated patient volumes and increased competition in the US
Orilissa forecast adjusted higher due to contribution from potential uterine fibroids label expansion
Veliparib forecast pushed out to align with timeline for regulatory submission
Navitoclax forecast added
ABBV-951 forecast added.
Model updates (8 November 2019)
Humira forecast adjusted lower internationally due to continued biosimilar impact
Skyrizi forecast adjusted higher due to robust launch in the US; international forecast adjusted lower due to slower launch in the five major EU markets and Rest of World
Upadacitinib name changed to Rinvoq
Imbruvica forecast adjusted higher globally due to recent inflection in market share in first-line CLL.
Model updates (29 July 2019)
Humira sales adjusted lower due to size of biosimilar impact in the five major EU markets and Rest of World regions
Skyrizi sales adjusted higher due to pace of product launch
Mavyret sales adjusted significantly lower due to declining markets and pricing pressure in international geographies
Orilissa sales adjusted lower due to slower initial product ramp
Rova-T forecast removed due to disappointing safety and efficacy data from Phase II TRINITY study
Upadacitinib launch forecast updated
Atrasentan forecast removed.
Table of Contents
Key Drug & Company Information
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726